Lyudmila Suplotova

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Raymond L. Forbes, A. Astrup, F. Greenway, 2017, The Lancet.

Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

T. Fülöp, Z. Kamenov, J. Gumprecht, 2022, Cardiovascular Diabetology.

Four-Hour Evaluation of a Medical Food in Subjects with Type 2 Diabetes Receiving Oral Hypoglycemic Medication

A. Voss, V. Mustad, L. Ruyatkina, 2012 .

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

John E. Poremba, H. Randeva, P. Borne, 2024, The Lancet.